XNAS · Healthcare · Biotechnology
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | Q1 2026 | -0.99 | -1.01 | -2.02% | $3.0M | ❌ Miss | +0.00% | +3.63% | +14.93% |
| 2026-03-18 | Q4 2025 | -0.53 | 0.43 | +181.13% | $85.1M | ✅ Beat | +3.97% | +15.42% | +22.55% |
| 2025-11-10 |
| Q3 2025 |
| -1.00 |
| -1.01 |
| -1.00% |
| $90,000 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-11 | Q2 2025 | -0.77 | -0.98 | -27.27% | $15,000 | ❌ Miss | +1.24% | +31.46% | +25.50% |
| 2025-05-08 | Q1 2025 | -0.86 | -0.86 | +0.00% | $14,000 | ➖ Inline | — | — | — |
| 2025-02-28 | Q4 2024 | -0.83 | -0.90 | -8.43% | $1,000 | ❌ Miss | — | — | — |
| 2024-11-13 | Q3 2024 | -0.70 | -0.79 | -12.86% | $3,000 | ❌ Miss | — | — | — |
| 2024-08-08 | Q2 2024 | -0.71 | -0.63 | +11.27% | $5,000 | ✅ Beat | — | — | — |
Showing last 8 quarters.